BIOCIENCIAS: Bª Y CLÍNICA DEL CÁNCER Y MEDIC. TRASLACIONAL
Escuela de doctorado
ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Publicaciones en las que colabora con ENRIQUE MARÍA OCIO SAN MIGUEL (51)
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma
Cells, Vol. 10, Núm. 3
2019
-
Drug-induced thrombotic microangiopathy during maintenance treatment in a patient with multiple myeloma
HemaSphere, Vol. 3, Núm. 3
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
-
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712
2017
-
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Journal of Hematology and Oncology, Vol. 10, Núm. 1
2016
-
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 1b study from GELTAMO group
British Journal of Haematology, Vol. 173, Núm. 2, pp. 245-252
-
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Blood, Vol. 127, Núm. 25, pp. 3165-3174
-
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance
Blood, Vol. 127, Núm. 15, pp. 1896-1906
2015
-
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
Leukemia, Vol. 29, Núm. 3, pp. 705-714
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
-
Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy
Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516
-
Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification
Leukemia, Vol. 28, Núm. 1, pp. 166-173
-
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease
Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305
2013
-
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
Leukemia, Vol. 27, Núm. 10, pp. 2056-2061
-
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Haematologica, Vol. 98, Núm. 1, pp. 79-86
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598